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Abstract
Recent studies have emphasized a role of adaptive immunity, and particularly T cells, in the
genesis of hypertension. We sought to determine the T cell subtypes that contribute to
hypertension and renal inflammation in angiotensin II-induced hypertension. Using T cell receptor
(TCR) spectratyping to examine TCR usage we demonstrated that CD8+ cells, but not CD4+ cells,
in the kidney exhibited altered TCR transcript lengths in Vβ3, 8.1 and 17 families in response to
angiotensin II-induced hypertension. Clonality was not observed in other organs. The hypertension
caused by angiotensin II in CD4−/− and MHCII−/− mice was similar to that observed in WT mice,
while CD8−/− mice and OT1xRAG-1−/− mice, which have only one TCR, exhibited a blunted
hypertensive response to angiotensin II. Adoptive transfer of pan-T cells and CD8+ T cells but not
CD4+/CD25− cells conferred hypertension to RAG-1−/− mice. In contrast, transfer of CD4+/
CD25+ cells to wild type mice receiving angiotensin II decreased blood pressure. Mice treated
with angiotensin II exhibited increased numbers of kidney CD4+ and CD8+ T cells. In response to
a sodium/volume challenge, wild type and CD4−/− mice infused with angiotensin II retained water
and sodium whereas CD8−/− mice did not. CD8−/− mice were also protected against angiotensin-
induced endothelial dysfunction and vascular remodeling in the kidney. These data suggest that in
the development of hypertension, an oligoclonal population of CD8+ cells accumulate in the
kidney and likely contribute to hypertension by contributing to sodium and volume retention and
vascular rarefaction.
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INTRODUCTION
Hypertension affects 30% of adults in Western populations and predisposes to myocardial
infarction, stroke, heart failure and renal failure.1, 2 Despite the prevalence of this disease,
the etiology of hypertension in most adults is unknown and perturbations of the central
nervous system, the kidney and the vasculature have been implicated. Recently our
laboratory and others have demonstrated a role of inflammation and the adaptive immune
system in the genesis of hypertension.3, 4 Several studies have shown that RAG-1−/− mice,
which lack lymphocytes, are partly protected against hypertension caused by angiotensin II,
DOCA-salt challenge and norepinephrine. Adoptive transfer of T cells restores hypertension
in these animals. Very recently, Mattson et al. have shown that T cells play a role in
hypertension in Dahl salt sensitive rats.5 Recent data suggests that T cells release cytokines
that mediate sodium retention in the kidney and vasoconstriction.4
Our laboratory has previously found that both CD4+ and CD8+ T cells accumulate in aortic
perivascular fat of hypertensive mice. CD4+ T regulatory cells have been shown to be
protective against hypertension and end organ damage.6 Despite these findings, there is little
information on the relative importance of CD4+ and CD8+ T cells and whether hypertension
is dependent on expansion of specific T cell clones. The purpose of this investigation is to
determine the T cell subtypes involved in the genesis of hypertension. We hypothesized that
T cells in the kidney and vasculature would exhibit altered T cell receptor (TCR) usage in
response to angiotensin II-induced hypertension. We found that CD8+ but not CD4+ T cells
in the kidney exhibited altered T cell receptor usage. We examined the role of CD4+ and
CD8+ T cells using mice lacking these subtypes and mice lacking CD8+ T cells were
protected against hypertension. Further, CD8+ T cells seem to modulate renovascular
remodeling and promote the anti-natiruetic and anti-diuretic effects of angiotensin II.
MATERIALS AND METHODS
Animals studied
Hypertension was produced in Wild type, RAG-1−/−, CD4−/−, CD8−/− and MCHII−/−, and
OT1xRAG-1−/− male mice by infusion of angiotensin II (490 ng/kg/min) for two weeks.
Blood pressure was measured both invasively using telemetry and non-invasively using the
tail cuff method as previously described.3 Flow cytometry, vascular reactivity in mesenteric
arteries, sodium and volume challenge experiments and kidney vascular morphology
analyses are described in detail in the online supplement.
T cell Receptor Analysis
TCR Vβ spectratyping was performed using PCR with a forward primer for each of the 24
TCR Vβ genes and a constant reverse primer for the Cβ gene labeled with FAM on the 5′
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end (Table S1). TCR deep sequencing was performed in spleen, mesenteric and renal CD8+
T cells as detailed in the supplemental methods and described previously.7, 8
Detailed materials and methods are provided in the online supplement.
RESULTS
The effect of hypertension on T cell receptor clonality
T cell activation occurs upon presentation of antigenic peptides by major histocompatibility
complexes, leading to proliferation of T cell clones that are specific for individual antigens.
The Vβ region of the TCR gene exhibits enormous diversity and analysis of this region can
provide insight into adaptive immune responses. The presence of a dominant transcript
length for a given Vβ family is indicative of clonal expansion and provides insight into the
antigenic repertoire responsible for T cell activation.9, 10 We therefore performed
spectratyping analysis of CD4+ and CD8+ T cells isolated from the spleen, mesenteric
vascular arcade and the kidneys of mice treated with vehicle or angiotensin II. In the spleen
both CD4+ and CD8+ TCR Vβ families exhibited a Gaussian distribution in both sham and
angiotensin II treated mice, indicative of a relatively naïve pool of T cells (Figure 1A, B).
Greater TCR transcript length variability was exhibited in mesentery (Figure 1C, D) and
kidney (Figure 2A, B). In many Vβ families, in both kidney and mesentery, there was
considerable variation in the spectratyping profiles regardless of presence or absence of
angiotensin II. To determine whether the transcript length distribution was consistently
altered across mice that received angiotensin II and to detect the presence of dominant
transcript lengths, Dirichelet and MaGiK analyses were employed.11, 12 T cell receptor
spectratyping profiles from the spleen and mesenteric vasculature CD4+ and CD8+ cells as
well as kidney CD4+ cells revealed no statistical differences when comparing sham to
angiotensin II treated mice (n = 8–10 per group). In contrast, angiotensin II resulted in the
presence of dominant transcript lengths in kidney T cell CD8+ Vβ 3, 8.1, and 17 families
(Figure 2C–E).
In additional studies, we employed deep sequencing of CD8+ TCR to provide further insight
into potential clones involved in the hypertensive response. In kidney CD8+ T cells, deep
sequencing revealed 4341 ± 514 unique TCR sequences in sham mice and 3522 ± 1049
unique TCR sequences in mice treated with angiotensin II (n = 5 per group). The most
commonly shared clonotypes among angiotensin II treated mice included 3 clonotypes
which were shared by 4 out of 5 angiotensin II treated mice and 2 that were shared by 3 out
of 5 angiotensin II treated mice (Table 1). These clonotypes were not present in multiple
sham mice. Notably, the clone with amino acid sequence CASSDNTEVFF observed in
angiotensin II treated mice exists in the Vβ8.1 family and is identical to the dominant
transcript length observed by spectratyping (Figure 2D). We found that these unique
sequences were also present in the spleen, but their frequencies were low and not different
between sham and angiotensin II-treated mice. The sequences shared by angiotensin II
treated mice in the kidney were not present in the mesentery.
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The role of T cell subtypes in hypertension
The specific skewing of CD8+ T cells, rather than CD4+ cells was surprising. We therefore
performed additional experiments to examine the roles of these cells in hypertension. We
infused angiotensin II for 14 days into wild type (WT), CD4−/− and CD8−/− mice. Both
systolic and diastolic blood pressures were significantly increased in WT and CD4−/− mice
(Figure 3A, B). In contrast, the angiotensin II-induced increase in blood pressure was
blunted in CD8−/− mice (Figure 3A, B). MCHII−/− mice, an alternate model of CD4+
deficiency, also exhibited increased blood pressure in response to angiotensin II (Figure 3A,
B). To determine whether an alternate model of hypertension is also dependent on CD8+ T
cells we induced DOCA-salt hypertension in WT, CD8−/− and CD4−/− mice. The increase in
blood pressure in response to DOCA-salt challenge was significantly reduced in CD8−/−
mice compared to either CD4−/− or WT mice (Figure S1), similar to angiotensin II-induced
hypertension.
To determine whether mice with an altered TCR phenotype are resistant to hypertension, we
infused angiotensin II or vehicle in OT1xRAG-1−/− mice, which possess a transgene for a
TCR specific for ovalbumin peptide OVA257–264 presented on MHC I. These mice are on a
RAG-1−/− background and therefore cannot generate endogenous TCRs. The angiotensin II-
induced increases in both systolic and diastolic blood pressures were blunted in
OT1xRAG-1−/− mice compared to those observed in WT, CD4−/− and MHCII−/− mice, but
were similar to the pressures observed in CD8−/− mice (Figure 3A, B).
To gain further insight into T cell subtypes in hypertension, adoptive transfer experiments
were performed. As previously reported, angiotensin II had only a modest effect on blood
pressure in RAG-1−/− mice3, 13, whereas adoptive transfer of pan T cells from WT mice that
had received angiotensin II for 2 weeks increased blood pressure to approximately 160
mmHg in the recipient RAG-1−/− mice (Figure 3C). Adoptive transfer of CD4+/CD25− cells
from angiotensin II treated mice into RAG-1−/− mice had no effect on blood pressure
(Figure 3C). In contrast, adoptive transfer of CD8+ cells caused a striking elevation in blood
pressure to greater than 180 mmHg (Figure 3C). As previously reported,6 adoptive transfer
of CD4+/CD25+ T regulatory cells to wild-type mice on day 9 of angiotensin II infusion
lowered blood pressure (Figure 3D).
Leukocyte Accumulation in Kidney and Vasculature
Flow cytometry was employed to determine the whether angiotensin II alters the T cell
subtypes present in the kidney. Angiotensin II infusion caused a 3-fold increase in both
CD8+ and CD4+ T cells in the kidney (Figure 4A, B). To determine whether CD8+ T cells
orchestrate angiotensin II-induced accumulation of leukocytes in the vasculature aortas form
wild type and CD8−/− mice were also analyzed. The accumulation of CD45+ leukocytes was
greater in wild type compared to CD8−/− mice (Figure S2).
Role of CD8+ and CD4+ T cells on responses to sodium and volume challenge
To determine the effect of T cell subsets on sodium and volume retention, studies were
performed in which mice received an intraperitoneal injection of normal saline equal to 10%
of their body weight at various times before and during angiotensin II infusion. At baseline
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(day-1), mice excreted more than 80% of this challenge in 4 hours, independent of their T
cell populations (Figure 4C). In WT mice, angiotensin II infusion induced a modest
retention of volume and NaCl compared to baseline values that persisted through day 10
(Figure 4C–E). In CD4−/− mice, volume and NaCl retention was similar to that in WT mice
on day 2, but on day 5, CD4−/− mice excreted only about 20% of the volume and NaCl
challenge (Figure 4C–E). In contrast, CD8−/− mice were protected against urinary volume
and NaCl retention at all times following onset of angiotensin II infusion (Figure 4C–E).
Taken together, these data illustrate that CD8+ T cells play a critical role in the anti-diuretic
and anti-natriuretic responses to angiotensin II.
Effect of CD8+ T cells on renal vascular remodeling in hypertension
To determine if inflammatory T cells mediate vascular remodeling in the kidney during
hypertension we examined renal vascular volume using microCT angiography (Figure 5A).
Total kidney and cortical vascular volumes were decreased with angiotensin II in WT and
CD4−/− mice but was persevered in CD8−/− mice (Figure 5B, C). Notably, a decrease in
vessels < 25 μm in diameter, represented by a loss of blue pseudo-color, appears to account
for the decrease in vascular volume with angiotensin II (Figure 5A). Medullary vascular
volume was decreased with angiotensin II in WT but not CD4−/− or CD8−/− mice (Figure
5D). To further characterize alterations in small arterioles, alpha actin staining was
employed. In these small vessels, media-to-lumen ratio was increased in WT and CD4−/−
mice but not CD8−/− mice (Figure 5E, F).
Role of T cell subtypes in vascular reactivity
To examine vascular reactivity, we studied 2nd and 3rd order mesenteric arteries, which are
involved in modulation of vascular resistance, in a wire myograph preparation.
Endothelium-dependent relaxations in response to acetylcholine were impaired in vessels of
WT and CD4−/− mice, compared to arteries of sham infused wild-type mice. In contrast,
angiotensin II did not impair endothelium-dependent relaxation in vessels of CD8−/− mice
(Figure 6A). Endothelium-independent relaxations were not altered (Figure 6B).
DISCUSSION
In the current study, we sought to determine the nature of T cells involved in the genesis of
hypertension by examining clonality in various organs involved in hypertension and by
examining the role of T cell subtypes. Spectratyping of TCRs revealed the development of
dominant transcript lengths in kidney CD8+ T cell Vβ3, 8.1 and 17 families following
angiotensin II infusion. Deep sequencing of renal CD8+ cells revealed five sequences that
were shared by angiotensin II treated mice. Mice that lacked CD8+ T cells or endogenous
TCRs exhibited blunted pressor responses to angiotensin II. Adoptive transfer of pan T cells
or CD8+ T cells induced hypertension in RAG-1−/− mice infused with angiotensin II. Mice
that lacked CD8+ T cells were protected against angiotensin II-induced endothelial
dysfunction, renal salt and water retention and vascular rarefaction. These data suggest that
an oligoclonal population of CD8+ T cells accumulates in the kidney and that CD8+ T cells
promote sodium and volume retention and arterial rarefaction resulting in overt
hypertension.
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To determine whether the T cell response in the kidney is monoclonal, oligoclonal or
nonspecific, we employed TCR spectratyping. During T cell development in the thymus
recombination of the Variable (V), Junctional (J) and Diversity (D) regions of the TCR beta
chain occurs. In addition, terminal deoxynucleotidyl transferase facilitates random insertion
of nucleotides at the V/D and D/J junctions, ultimately leading to enormous TCR diversity
and specificity.14 In naïve pools of T cells this results in a Gaussian distribution of TCR
gene transcript lengths. Spectratyping allows analysis of TCR transcript lengths and
detection of non-Gaussian distributions. The presence of TCR dominant transcript lengths
strongly suggests clonal expansion.9 Such analyses have revealed clonal expansion in the
context of infection 15 and autoimmune disease.16 More recently, this has also been
observed in models of atherosclerosis 17 and obesity.18, 19 We found that angiotensin II
infusion resulted in dominant TCR transcript lengths in CD8+ T cells within the Vβ3, 8.1
and 17 TCR families in the kidney, while not altering the distributions within CD4+ cells or
either CD4+ or CD8+ T cells in the spleen or mesenteric vasculature. While perturbations of
both the vasculature and kidney have been shown to be involved in hypertension, the
accumulation of a unique population of CD8+ T cells in the kidney suggests that this might
be a primary site for immune activation in hypertension.
To gain further insight into TCRs involved in hypertension, we also employed deep
sequencing of kidney, spleen and mesentery CD8+ TCRs. This approach provides a
complete overview of the amino acid sequences of the TCR CDR3 region, which is the
region of the TCR that binds to antigen.7, 8 We found that five CD8+ TCR sequences in the
kidney were shared by multiple angiotensin II-treated mice. Of note, the CASSDNTEVFF
clone is of the same transcript length as the dominant length observed within the Vβ8.1
family identified by spectratyping. Importantly, these sequences were not shared with sham
mice. These sequences were not found in the mesenteric vasculature and found in both sham
and angiotensin II treated mice in the spleen. The presence of these sequences in the spleens
of both sham and angiotensin II-treated mice suggests that these sequences exist in the naïve
pool of T cells in all animals and that unique sequences are mobilized to the kidney in
hypertension. The presence of TCR sequences shared by angiotensin II treated mice
exclusively in the kidney together with the skewing of selected TCR Vβ family transcript
lengths in the kidney suggests that the kidney might represent a site of neoantigen formation
in hypertension.
In unusual instances, such as T cell leukemia, a single TCR clone can account for up to 50%
of the total TCR usage.20 In contrast, we found that clones shared among hypertensive mice
represent less than 0.2% of all CD8+ TCR transcripts in the kidney. This is similar to shared
clonotypes of islet infiltrating T cells in mice with type one diabetes.21 The relatively low
frequency of unique TCR clonotypes in hypertensive mice is consistent with a common
pattern of inflammation where specific T cell clones are first activated, followed by
infiltration of other T cells unrelated to the initial clone that then contribute to the
inflammatory response.22 In addition, in a region of inflammation, there may be
development of other antigens, due to protein modifications that lead to activation of T cells
other than the originally stimulated clones. This phenomenon is often referred to as epitope
spreading,23 which can occur in response to either foreign proteins in infectious disease or to
self-proteins in the context of autoimmune disease. In addition, depending on the topology
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of the MHC complex and antigen peptide “public” or “private” T cell responses can occur.24
If the MHC/peptide complex has distinct features, a single T cell clone is likely to recognize
this complex across mice and this phenomenon is referred to as a public response. In
contrast, if the MHC/peptide complex is relatively featureless, a private response can occur,
where the TCR clones vary from one animal to the next. In summary, recruitment of non-
specific T cell clones, epitope spreading and public vs. private T cell response may explain
the generally low frequencies of unique TCR clonotypes in the kidneys of hypertensive
mice. The precise nature of potential neoantigens involved in hypertension is an important
topic for future study.
Because we observed skewing of CD8+ T cell receptors in the kidney, we performed
additional studies to examine the role of these cells in hypertension. Interestingly, we found
the hypertensive response to angiotensin II was blunted in CD8−/−, but not in CD4−/− mice.
We also found that mice lacking MHCII, which are also deficient in CD4+ cells, were not
protected against hypertension. These data indicate that not only is there alteration of CD8+
TCR sequences, but that these cells likely contribute to the elevation of blood pressure in
response to angiotensin II. Importantly, Youn et al. recently demonstrated that
proinflammatory immunosenescent CD8+ cells are increased in humans with
hypertension.25
It is possible that the renal inflammation promotes inflammation in other organs. In keeping
with this, we found that total leukocyte accumulation in the aorta of CD8−/− mice with
angiotensin II treatment was less than that of wild type mice. One explanation for this is the
reduced systemic pressure in the CD8−/− mice. In a recent study, we found that lowering
blood pressure with hydralazine and hydrochlorothiazide markedly reduced vascular
inflammation in response to chronic angiotensin II infusion.26
As we observed that hypertension is associated with alterations in TCR receptor usage in the
kidney, we sought to determine if mice with an altered TCR repertoire would be protected
against hypertension. The pressor response in OT1xRAG-1−/− mice, which do not posses
endogenous TCR, is similar in magnitude to that observed in RAG-1−/− mice.3 This supports
the concept that endogenous TCR are required for the development of overt hypertension. If
the T cell response in hypertension were nonspecific, these mice would be expected to
develop hypertension in a similar manner to wild type mice. We employed OT1xRAG-1−/−
mice, as OT1 mice, despite a heavily skewed TCR repertoire, can still generate endogenous
TCR, whereas OT1xRAG-1−/− mice cannot.27
Hypertensive stimuli such as angiotensin II have an anti-natriuretic effect, promoting an
increase in intravascular volume. This is then followed by an increase in systemic vascular
resistance, or systemic autoregulation, which is accompanied by alterations in vascular tone,
arterial remodeling and vascular rarefaction. Our current findings suggest that CD8+ T cells
act as an intermediate in angiotensin II-induced endothelilal dysfunction, vascular
rarefaction and sodium and volume retention, key processes in the development of
hypertension.28 Importantly, 25% of the cardiac output is directed to the kidneys. The loss in
renal cortical arterioles and the resultant increase in systemic vascular resistance, likely
contributes to hypertension. In addition, it is conceivable that decreased kidney blood flow
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may contribute to enhanced sodium and water reabsorption, also leading to increased blood
pressure.
Our studies should not be interpreted as indicating that there is no role of CD4+ T cells in
hypertension. The development of memory CD8+ T cells depends on CD4+ cell help.29 In
addition, CD8+ T regulatory cells also exist and can exert anti-inflammatory effects in a
similar manner to CD4+ T regulatory cells.30 We found greater numbers of both CD4+ and
CD8+ T cells in the kidneys of hypertensive mice. Recent reports from our laboratory have
also shown that CD4+ and CD8+ T cells accumulate in the aortas of hypertensive mice.3, 26
In RAG-1−/− mice, transfer of CD4+ cells from which CD25+ cells had been depleted, (thus
excluding most T regulatory cells), did not raise blood pressure. Transfer of CD8+ cells
alone caused a greater elevation in blood pressure than pan-T cells, suggesting that CD4+
cells play a protective role. Similarly, blood pressure in CD4−/− mice was greater than that
of wild type mice in the DOCA salt experiments. Importantly, CD4−/− mice lack CD4+
regulatory cells, which are protective in hypertension.6 In accord with this observation we
found that adoptive transfer of CD4+/CD25+ (primarily T regulatory cells) decreased blood
pressure in wild type animals. These findings are consistent with ample evidence for
inhibition of CD8+ T cells by CD4+ regulatory cells.31, 32 Taken together, these studies
confirm a unique pro-hypertensive role of CD8+ T cells.
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Our data suggest that CD8+ T cells have an important role in hypertension and provide
evidence that there is an oligoclonal response of these cells in the kidney. These cells
help coordinate alterations in renal and vascular function that ultimately lead to
hypertension and end organ dysfunction caused by hypertensive stimuli. One explanation
for these results is that unique neoantigens develop in the hypertensive kidney and are
presented in the context of MHC I. Our findings allow new insight into understanding
hypertension and potentially provide new therapeutic directions for treatment in this
disease and its end-organ damage.
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• T cells have been shown to play a role in the development of hypertension, this
study demonstrates that a specific subset of CD8+ T cells play a critical role in
hypertension
• These CD8+ T cells have altered T cell receptors, suggesting an immune
response to a neoantigen in kidney
What is relevant?
• The identification of this subset of CD8+ T cells provides insight into the
development of high blood pressure and a potential target for future treatment
Summary
• In the development of hypertension, a subset of CD8+ T cells act to decrease
small blood vessel number and size in the kidney and contribute to the retention
of salt and water, causing an increase in blood pressure
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Sample TCR Vβ Family Spectratype Profiles from Spleen and Mesenteric Vasculature. Mice
were made hypertensive by infusion of angiotensin II (Ang II, 490 ng/kg/min) for 14 days.
CD4+ and CD8+ T cells were isolated from the spleen or mesentery, mRNA isolated and
reverse transcribed to cDNA. PCR was performed using 24 different Vβ primers and a
single FAM labeled Cβ primer. The resulting fragment profiles were visualized using Peak
Scanner software from Applied Biosystems. A) Spleen sample distributions for each CD4+
Vβ family from sham and angiotensin II treated mice. B) Spleen sample distributions from
CD8+ Vβ families. C) Mesentery sample distributions from CD4+ Vβ families. C)
Mesentery sample distributions from CD8+ Vβ families. Vβ families not shown were
undetectable.
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TCR Vβ Family Spectratype Profiles from Kidney T cells. Samples were prepared from the
kidneys of sham and angiotensin II (Ang II)-infused mice as described in figure 1. A)
Kidney sample distributions for each CD4+ Vβ family from sham and angiotensin II treated
mice. B) Kidney sample distributions from CD8+ Vβ families. Vβ families not shown were
undetectable. TCR length profiles were analyzed using Applied Biosystems Peak Scanner
software and the area under each peak at a given transcript length was divided by the total
area under all peaks to determine the relative frequency of each individual transcript length.
Frequency distributions are shown for CD8+ C) Vβ3, D) Vβ8.1 and E) Vβ17 families.
Spectratyping profiles were p values determined by Dirichelet distribution and the MaGiK
analysis, n = 8–10 per group.
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Role of T cell subtypes in angiotensin II (Ang II)-induced hypertension. Wild-type (WT, n =
4), CD4−/− (n = 5), CD8−/− (n = 5), MHCII−/− (n = 6) and OT1xRAG-1−/− (n = 10) mice
received angiotensin II (490 ng/kg/min) for 15 days via osmotic minipumps. Blood pressure
was monitored by telemetry and values represent day/night averages for each group during
the last 3 days of infusion. A) Baseline systolic (top) and diastolic blood pressures (bottom)
B) 14 day systolic (top) and diastolic blood pressures (bottom). C) Adoptive transfer of T
cells into RAG-1−/− mice. RAG-1−/− mice received angiotensin II (Ang II) via osmotic
minipump starting at day 0 and at day 10 received no cells, pan T cells, CD4+/CD25− or
CD8+ T cells from WT mice (n = 7–9 per group) that had previously received angiotensin II
for 2 weeks. Blood pressure was measured by tail cuff. D) Adoptive transfer of CD4+/
CD25+ into WT mice. Both groups received Ang II starting at day 0 and at day 9 received
no cells or CD4+/CD25+ T cells from untreated WT mice. (n = 5 per group) P values for
blood pressure were determined using repeated measures ANOVA and a Student Newman
Keuls post-hoc test. D = day, N = night.
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Renal T cells accumulation and their role in the anti-diuresis and anti-natriuresis caused by
angiotensin II (Ang II). Kidney single cell suspensions from sham and Ang II treated mice
were subjected to flow cytometry for analysis of CD4+ and CD8+ T cell accumulation. A)
Sample flow cytometry plots and B) Absolute numbers of CD4+ and CD8+ cells per kidney.
n = 6 per group p values determined by unpaired t test. C) urine, D) sodium and E) chloride
output over 4 hours in response to 10% of mouse body weight in saline IP on the days
indicated (n = 5–6 per group). P values represent changes from baseline determined by
repeated measures ANOVA. B-Baseline 2-, 5-, 10-days of angiotensin II treatment.
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Effect of T cell subtypes on the kidney vascular structure. A) Representative CT models of
the kidney vasculature in sham and angiotensin II (Ang II) treated mice. Quantification of B)
total vascular volume (mm2), C) cortex vascular volume, D) medulla vascular volume (n =
3–5 per group). E) alpha actin staining for renal cortical arterioles in wild-type (WT),
CD4−/− and CD8−/− mice. F) Renal arterioles <25 mm in diameter and arteries > 25 mm
were quantified by planimetry (n = 4 per group). P values determined by 2 way ANOVA.
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Influence of T cell subtypes in angiotensin II-induced vascular dysfunction. Mice received
sham or angiotensin II (Ang II) infusions for 2 weeks as in figure 1. Second and third order
mesenteric vessels were mounted in wire myographs and pre-constricted with phenylephrine
(1 μm). A) Endothelium-dependent relaxations to acetylcholine and B) endothelium-
dependent independent relaxations to sodium nitroprusside (SNP) were then determined and
compared using ANOVA for repeated measures (n = 4–7 per group).
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